Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,396 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Single-Cell Phosphoproteomics Resolves Adaptive Signaling Dynamics and Informs Targeted Combination Therapy in Glioblastoma.
Wei W, Shin YS, Xue M, Matsutani T, Masui K, Yang H, Ikegami S, Gu Y, Herrmann K, Johnson D, Ding X, Hwang K, Kim J, Zhou J, Su Y, Li X, Bonetti B, Chopra R, James CD, Cavenee WK, Cloughesy TF, Mischel PS, Heath JR, Gini B. Wei W, et al. Among authors: herrmann k. Cancer Cell. 2016 Apr 11;29(4):563-573. doi: 10.1016/j.ccell.2016.03.012. Cancer Cell. 2016. PMID: 27070703 Free PMC article.
A1 adenosine receptors in microglia control glioblastoma-host interaction.
Synowitz M, Glass R, Färber K, Markovic D, Kronenberg G, Herrmann K, Schnermann J, Nolte C, van Rooijen N, Kiwit J, Kettenmann H. Synowitz M, et al. Among authors: herrmann k. Cancer Res. 2006 Sep 1;66(17):8550-7. doi: 10.1158/0008-5472.CAN-06-0365. Cancer Res. 2006. PMID: 16951167
Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022.
Gillessen S, Bossi A, Davis ID, de Bono J, Fizazi K, James ND, Mottet N, Shore N, Small E, Smith M, Sweeney CJ, Tombal B, Antonarakis ES, Aparicio AM, Armstrong AJ, Attard G, Beer TM, Beltran H, Bjartell A, Blanchard P, Briganti A, Bristow RG, Bulbul M, Caffo O, Castellano D, Castro E, Cheng HH, Chi KN, Chowdhury S, Clarke CS, Clarke N, Daugaard G, De Santis M, Duran I, Eeles R, Efstathiou E, Efstathiou J, Ekeke ON, Evans CP, Fanti S, Feng FY, Fonteyne V, Fossati N, Frydenberg M, George D, Gleave M, Gravis G, Halabi S, Heinrich D, Herrmann K, Higano C, Hofman MS, Horvath LG, Hussain M, Jereczek-Fossa BA, Jones R, Kanesvaran R, Kellokumpu-Lehtinen PL, Khauli RB, Klotz L, Kramer G, Leibowitz R, Logothetis C, Mahal B, Maluf F, Mateo J, Matheson D, Mehra N, Merseburger A, Morgans AK, Morris MJ, Mrabti H, Mukherji D, Murphy DG, Murthy V, Nguyen PL, Oh WK, Ost P, O'Sullivan JM, Padhani AR, Pezaro CJ, Poon DMC, Pritchard CC, Rabah DM, Rathkopf D, Reiter RE, Rubin MA, Ryan CJ, Saad F, Sade JP, Sartor O, Scher HI, Sharifi N, Skoneczna I, Soule H, Spratt DE, Srinivas S, Sternberg CN, Steuber T, Suzuki H, Sydes MR, Taplin ME, Tilki D, Türkeri L, Turco F, Uemura H, Uemura H, Ürün Y, Va… See abstract for full author list ➔ Gillessen S, et al. Among authors: herrmann k. Eur J Cancer. 2023 May;185:178-215. doi: 10.1016/j.ejca.2023.02.018. Epub 2023 Mar 3. Eur J Cancer. 2023. PMID: 37003085 Free article.
Correlation analyses of radiographic progression-free survival with clinical and health-related quality of life outcomes in metastatic castration-resistant prostate cancer: Analysis of the phase 3 VISION trial.
Morris MJ, de Bono J, Nagarajah J, Sartor O, Wei XX, Nordquist LT, Koshkin VS, Chi KN, Krause BJ, Herrmann K, Rahbar K, Vickers A, Mirante O, Ghouse R, Fizazi K, Tagawa ST. Morris MJ, et al. Among authors: herrmann k. Cancer. 2024 Oct 15;130(20):3426-3435. doi: 10.1002/cncr.35438. Epub 2024 Jun 21. Cancer. 2024. PMID: 39031642 Clinical Trial.
Does regression of skin thickening predict improvement of internal organ involvement and survival in patients with diffuse cutaneous systemic sclerosis? A EUSTAR analysis.
Wyss A, Jordan S, Graf N, Carreira PE, Distler J, Cerinic MM, Siegert E, Henes J, Zanatta E, Riccieri V, Truchetet ME, Oksel F, Li M, Kucharz EJ, Eyerich K, Del Galdo F, Vonk MC, Vold AH, Gabrielli A, Distler O; EUSTAR collaborators. Wyss A, et al. Arthritis Res Ther. 2024 Oct 31;26(1):187. doi: 10.1186/s13075-024-03418-2. Arthritis Res Ther. 2024. PMID: 39482761 Free PMC article.
Assessment of the therapeutic efficacy of [177Lu]Lu-PSMA-X compared to taxane chemotherapy in taxane-chemo-naïve patients with metastatic castration-resistant prostate cancer: A systematic review and meta-analysis.
Almeida LS, García Megías I, Etchebehere ECSC, Calapaquí Terán AK, Herrmann K, Giammarile F, Treglia G, Delgado Bolton RC. Almeida LS, et al. Among authors: herrmann k. Eur J Nucl Med Mol Imaging. 2024 Oct 25. doi: 10.1007/s00259-024-06932-2. Online ahead of print. Eur J Nucl Med Mol Imaging. 2024. PMID: 39453485
Head-to-head comparison of 68 Ga-FAPI-46 PET/CT, 18F-FDG PET/CT, and contrast-enhanced CT for the detection of various tumors.
Watanabe M, Fendler WP, Grafe H, Hirmas N, Hamacher R, Lanzafame H, Pabst KM, Hautzel H, Aigner C, Kasper S, von Tresckow B, Stuschke M, Kümmel S, Lugnier C, Hadaschik B, Grünwald V, Zarrad F, Kersting D, Siveke JT, Herrmann K, Weber M. Watanabe M, et al. Among authors: herrmann k. Ann Nucl Med. 2024 Oct 23. doi: 10.1007/s12149-024-01993-7. Online ahead of print. Ann Nucl Med. 2024. PMID: 39443386
Novel Radiopharmaceuticals and Future of Theranostics in Genitourinary Cancers.
Sollini M, Calais J, Chiti A, Emmett L, Fanti S, Fendler W, Herrmann K, Hope TA, Sartor O, Shuch B, Tagawa S, Hofman MS. Sollini M, et al. Among authors: herrmann k. Eur Urol. 2024 Oct 19:S0302-2838(24)02641-1. doi: 10.1016/j.eururo.2024.09.036. Online ahead of print. Eur Urol. 2024. PMID: 39428326 Review.
1,396 results